Corbus Pharmaceuticals
CRBP
103 hedge funds and large institutions have $155M invested in Corbus Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 35 reducing their positions, and 16 closing their positions.
0% more funds holding
Funds holding: 103 → 103 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
0.03% less ownership
Funds ownership: 1.67% → 1.64% (-0.03%)
31% less capital invested
Capital invested by funds: $224M → $155M (-$69.4M)
40% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 35
44% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $2.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$1.27M |
| 2 |
BlackRock
New York
|
+$772K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$471K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$455K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$355K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.23M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.23M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.08M |
| 4 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$707K |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$482K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
101
Virtu Financial
New York
| – | -$199K | -955 | Closed |
|
|
ECM
102
ExodusPoint Capital Management
New York
| – | -$132K | -636 | Closed |
|
|
WG
103
Winton Group
London,
United Kingdom
| – | -$97K | -466 | Closed |
|
|
CAN
104
Cetera Advisor Networks
El Segundo,
California
| – | -$96K | -463 | Closed |
|
|
DTL
105
Dynamic Technology Lab
Singapore
| – | -$71K | -341 | Closed |
|
|
AG
106
Aperio Group
Sausalito,
California
| – | -$29K | -142 | Closed |
|
|
EWM
107
Executive Wealth Management
Brighton,
Michigan
| – | -$7K | -33 | Closed |
|
|
FANJ
108
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$1K | -7 | Closed |
|
109
Parallax Volatility Advisers
San Francisco,
California
| – | -$1K | -7 | Closed |
|
110
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$1K | -6 | Closed |
|
111
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | -4 | Closed |
|
|
TWA
112
TCI Wealth Advisors
Tucson,
Arizona
| – | -$523 | -3 | -50% |
|
CRBP Hedge Fund Activity: Q3 2019 in Review
103 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2019, worth a combined $155M — down 31% from $224M a quarter earlier.
Fund positioning in CRBP was balanced in Q3 2019: 16 funds opened new positions, 16 closed out, 21 added to existing stakes and 35 trimmed.
The largest buyer was Russell Investments Group, opening a new position worth an estimated $1.27M. The largest seller was Millennium Management, exiting entirely with an estimated $5.23M sold.
- 103 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $155M of Corbus Pharmaceuticals stock for Q3 2019, down 31% quarter-over-quarter.
- 16 funds opened new Corbus Pharmaceuticals positions in Q3 2019 and 16 closed out, a net change of 0 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2019 was Russell Investments Group, an estimated $1.27M added.
- The largest Corbus Pharmaceuticals seller in Q3 2019 was Millennium Management, an estimated $5.23M sold.
Based on aggregated 13F filings for Q3 2019.